CO 002
Alternative Names: CO-002Latest Information Update: 17 Jan 2024
At a glance
- Originator CellOrigin
- Class Antineoplastics; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Macrophage replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Dec 2023 Preclinical trials in Solid tumours in China (Parenteral) prior to December 2023 (CellOrigin pipeline, December 2023)